The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory

Summary: Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against COVID-19. Clinical trials and ongoing vaccinations present with varying degrees of protection levels and side effects. However, the drivers of the reported side eff...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sonia Ndeupen, Zhen Qin, Sonya Jacobsen, Aurélie Bouteau, Henri Estanbouli, Botond Z. Igyártó
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Q
Acceso en línea:https://doaj.org/article/8c4e06d68ede410195a0440cfbbaaac1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares